Imaging Biomarkers in Metastatic Prostate Cancer
The second most common cause of cancer death in men is prostate cancer. The most severe form of the disease is metastatic castration-resistant prostate cancer (mCRPC), which is marked by soft tissue and bone metastasis that progress even in the presence of reduced hormone levels. Modern treatment regimens have demonstrated overall survival at 5 years at ~25%, which is great progress, however, there remains a high unmet medical need for treatment as well as improved biomarkers.
The diagnosis, staging, treatment planning and monitoring of mCRPC relies on a combination of clinical tests, including several standard and advanced imaging methods.
In this webinar, Dr. Silva and Dr. Kuo will review standard of care imaging in mCRPC and introduce nuclear medicine methods that monitor disease and drug targets, such as PSMA. They will also review multi-parametric MRI methods that aim to improve the characterization of disease and monitoring of drug treatment. Finally the webinar will demonstrate how our advanced analytical tools can assist radiologists and oncologists in the evaluation of metastatic disease status and response to therapy.
Dr. Matthew Silva serves as Executive Vice President of Scientific and Medical Services at Invicro, backed by 20 years of diverse technical and management experience from pharmaceutical and contract research organizations. Dr. Silva has been with Invicro for over 5 years and has core responsibilities to grow the oncology and systemic diseases strategy, while focusing on imaging biomarker applications to support drug discovery and development. Prior to Invicro, Dr. Silva was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the in vivo imaging and histopathology groups supporting discovery and clinical. Previously, Dr. Silva led imaging groups at Amgen, Millennium and Takeda Pharmaceuticals, during which he supported broad use of imaging biomarkers to support drug discovery and development. He holds a Ph.D. and M.S. in Biomedical Engineering from Worcester Polytechnic Institute and a B.S. in Biomedical Engineering from Boston University.
Dr. Phillip Kuo has over nine years of experience designing and reading for oncology and neurology-based clinical trials. Dr. Kuo received his BA in Chemistry from Harvard University. He continued his pursuit of higher education at the University of Virginia where he earned both an MS and PhD in Molecular Physiology and Biological Physics and then his MD in 2000. Dr. Kuo completed his Internal Medicine Residency training at UCLA and fellowship in Nuclear Medicine at Yale New Haven Hospital. He holds board certifications in Nuclear Medicine, Radiology, Internal Medicine and Nuclear Cardiology. He holds the academic appointment of Professor of Medical Imaging, Medicine and Biomedical Engineering at the University of Arizona. He currently serves as Chief of Nuclear Medicine and Program Director for the Nuclear Radiology Fellowship. Scientific interests span basic, translational and clinical research in molecular imaging. He has published in numerous journals, such as Nature, The New England Journal of Medicine, Radiology, and The Journal of Nuclear Medicine. Currently, Dr. Kuo consults across Invicro to support design and performance of Phase 1-3 clinical trials, regulatory affairs and strategic vision.